Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus THERMAZENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus THERMAZENE.
BENZAMYCIN vs THERMAZENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and causing cell death. It also has anti-inflammatory effects by modulating cytokine release.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
1% cream applied topically once or twice daily; for burns, apply 1/16-inch thick layer over entire burn area.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Terminal elimination half-life is approximately 22 hours (range 17–28 h) in patients with normal renal function, enabling twice-daily dosing in most cases.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Renal: ~65% unchanged; biliary/fecal: ~35% as metabolites and unchanged drug.
Category C
Category C
Topical Antibiotic
Topical Antibiotic